{"id":6331,"date":"2024-03-01T12:18:42","date_gmt":"2024-03-01T12:18:42","guid":{"rendered":"https:\/\/www.nfp-drugs.bg\/en\/?p=6331"},"modified":"2024-03-01T12:18:42","modified_gmt":"2024-03-01T12:18:42","slug":"issue-12-of-news-bulletin-for-the-new-psychoactive-substances","status":"publish","type":"post","link":"https:\/\/www.nfp-drugs.bg\/en\/issue-12-of-news-bulletin-for-the-new-psychoactive-substances\/","title":{"rendered":"Issue 12 of NEWS bulletin for the new psychoactive substances"},"content":{"rendered":"\n<p>In issue 12 of the edition of the National Focal Point on Drugs and Drug Addictions NEWS \u2013 Bulletin for the new psychoactive substances you will find the following topics:<\/p>\n\n\n\n<ul>\n<li>New psychoactive substances identified in Bulgaria in 2023.<\/li>\n\n\n\n<li>New psychoactive substances placed under control in Bulgaria in 2023.<\/li>\n\n\n\n<li>New psychoactive substances identified in Europe in 2023.<\/li>\n\n\n\n<li>Increase in identified cases of nitazene opioids in Europe and associated poisonings.<\/li>\n\n\n\n<li>Protonitazepyne under intensive monitoring.<\/li>\n\n\n\n<li>6 semi-synthetic cannabinoids (SSCs) under intensive monitoring by EMCDDA.<\/li>\n\n\n\n<li>Tablets containing more than 300 mg of MDMA.<\/li>\n\n\n\n<li>Risk assessment of new psychoactive substances.<\/li>\n<\/ul>\n\n\n\n<p><strong><a href=\"https:\/\/www.nfp-drugs.bg\/en\/wp-content\/uploads\/2024\/03\/NEWS_12.pdf\">Issue 12 of NEWS (in Bulgarian)<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In issue 12 of the edition of the National Focal Point on Drugs and Drug Addictions NEWS \u2013 Bulletin for the new psychoactive substances you will find the following topics: Issue 12 of NEWS (in Bulgarian)<\/p>\n","protected":false},"author":1,"featured_media":6334,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[],"_links":{"self":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts\/6331"}],"collection":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/comments?post=6331"}],"version-history":[{"count":1,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts\/6331\/revisions"}],"predecessor-version":[{"id":6336,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts\/6331\/revisions\/6336"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/media\/6334"}],"wp:attachment":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/media?parent=6331"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/categories?post=6331"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/tags?post=6331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}